By using a mobile app and patient portal called MyQuest, “adult users can prompt the tool to define test names and medical ...

Lynk Pharmaceuticals has reported another phase 3 win in China for its next-gen JAK inhibitor, this time hitting skin clearance goals among patients with eczema. | Lynk Pharmaceuticals has reported ...

The Swiss drugmaker reported a phase 3 win for fenebrutinib over Sanofi's Aubagio in RMS in November. In that study, Roche linked its drug candidate to a 59% reduction in the annualized relapse rate ...

Aardvark Therapeutics has seen its share price halve in value after the company paused a phase 3 study of its lead metabolic asset over heart-related data.

A panel of physicians, biotech leaders and patient advocates took aim at the FDA during a Senate hearing Thursday on how the ...

BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...

On some level, Eli Lilly’s partnership with computing giant Nvidia feels inevitable. | On some level, Eli Lilly’s partnership with computing giant Nvidia feels inevitable. The first pharma to reach a ...

The FDA slammed ExThera with a warning letter for deviating from the regulatory agency’s guidelines by promoting and selling ...

A Chinese phase 3 trial of Bristol Myers Squibb’s antibody-drug conjugate has hit its dual primary survival endpoints, ...

A new biotech has taken flight as a result of Novartis’ red-hot $12 billion acquisition of muscular dystrophy specialist Avidity Biosciences. | A new biotech has risen from the ashes of Novartis’ ...

Following the launch of its Wegovy (semaglutide) pill at the beginning of the year, Novo Nordisk is committing as much as ...

Protara Therapeutics has touted a 66% complete response (CR) rate for its cell therapy among certain bladder cancer patients ...